← Browse by Condition
Medical Condition

hematologic malignancies

Total Trials
8
Recruiting Now
8
Trial Phases
Phase 1, Phase 1, Phase 2, Phase 2

ClinicalMetric tracks all active clinical trials for hematologic malignancies sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hematologic malignancies Clinical Trials

How many clinical trials are currently recruiting for hematologic malignancies?
ClinicalMetric currently tracks 8 actively recruiting clinical trials for hematologic malignancies, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hematologic malignancies?
hematologic malignancies research spans Phase 1 (2 trials), Phase 2 (3 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hematologic malignancies clinical trial?
Eligibility criteria for hematologic malignancies trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
3
Phase 3
1
Top Sponsors
Sichuan Baili Pharmaceutical Co., Ltd. 1 trial
Assistance Publique - Hôpitaux de Paris 1 trial
Sellas Life Sciences Group 1 trial
Tata Memorial Centre 1 trial
Technical University of Munich 1 trial

Recruiting Clinical Trials

NCT07255898 Phase 1
Recruiting
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Enrollment
33 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
View Trial →
NCT02884375
Recruiting
Elderly CAncer Patient
Enrollment
3,000 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
View Trial →
NCT04588922 Phase 1, Phase 2
Recruiting
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Enrollment
160 pts
Location
United States, China
Sponsor
Sellas Life Sciences Group
View Trial →
NCT07709013 Phase 2
Recruiting
Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients
Enrollment
22 pts
Location
India
Sponsor
Tata Memorial Centre
View Trial →
NCT04263857
Recruiting
Register of Blood Stem Cell Transplantation
Enrollment
5,000 pts
Location
Germany
Sponsor
Technical University of Munich
View Trial →
NCT04546945
Recruiting
Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
Enrollment
38 pts
Location
Egypt
Sponsor
Asmaa Hassan mohamed Abdel Maw...
View Trial →
NCT06665100 Phase 2
Recruiting
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Enrollment
100 pts
Location
United States
Sponsor
Pulmotect, Inc.
View Trial →
NCT07186192 Phase 3
Recruiting
Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy
Enrollment
190 pts
Location
United States
Sponsor
City of Hope Medical Center
View Trial →

Related Conditions

multiple myeloma (1) solid cancer (1) hematopoietic stem cell transplant hsct (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology